Completed PHASE3 INTERVENTIONAL 2-arm NCT00724126

Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS) (TARGET 2)

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin 550 mg TID in the Treatment of Subjects With Non-Constipation Irritable Bowel Syndrome

Sponsor: Bausch Health Americas, Inc.

Conditions Non-Constipation Irritable Bowel Syndrome

Interventions Placebo Rifaximin

Updated 9 times since 2017 Last updated: Nov 26, 2019 Started: Jul 31, 2008 Primary completion: Aug 31, 2009 Completion: Sep 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Non-Constipation Irritable Bowel Syndrome, this trial is completed. The trial is conducted by Bausch Health Americas, Inc. and has accumulated 9 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Dec 2019 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 4 earlier versions

Jun 2019 — Dec 2019 [monthly]

Completed PHASE3
Jun 2018 — Jun 2019 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jul 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bausch Health Americas, Inc.

Data source: Bausch Health Americas, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Anaheim, United States , Anderson, United States , Ann Arbor, United States , Anniston, United States , Atlanta, United States , Baltimore, United States , Birmingham, United States , Boca Raton, United States , Boone, United States and 75 more locations